Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
Joana G RodriguesHenrique O DuarteCatarina GomesMeritxell BalmañaÁlvaro M MartinsPaul J HensbergenArnoud H de RuJorge LimaAndré AlbergariaPeter A van VeelenManfred WuhrerJoana GomesCelso Albuquerque ReisPublished in: Cellular oncology (Dordrecht) (2021)
Our data indicate that EGFR ⍺2,6-sialylation is a key factor in modulating the susceptibility of CRC cells to antibody targeted therapy, thereby disclosing a potential novel biomarker and providing key molecular information for tailor made anti-cancer strategies.
Keyphrases
- endoplasmic reticulum stress
- epidermal growth factor receptor
- induced apoptosis
- tyrosine kinase
- advanced non small cell lung cancer
- signaling pathway
- electronic health record
- small cell lung cancer
- cell cycle arrest
- stem cells
- human health
- healthcare
- bone marrow
- cell death
- risk assessment
- artificial intelligence
- cell proliferation
- machine learning
- cell therapy
- social media
- pi k akt